Thursday, May 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Soligenix Wins Additional 4.3M to Advance Ricin Vaccine Manufacturing

by Global Biodefense Staff
May 5, 2016
Notable Biotechnology Contracts

Notable Biotechnology ContractsSoligenix, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option for RiVax™ bulk drug substance and finished drug product process scale-up and technology transfer.

The funding will support preclinical studies and manufacturing in accordance with current good manufacturing practices (cGMPs). The overall objectives of the contract are to advance the development of Soligenix’s thermostabilization technology, ThermoVax®, combined with the company’s ricin toxin vaccine, RiVax™, as a medical countermeasure to prevent the effects of ricin exposure.

See also: Thermostable Ricin Vaccine Gets Another Funding Boost

The exercised option for contract #HHSN272201400039C will provide Soligenix with an additional $4.3M in funding (total awarded to date under this contract:  $13.5M). If all contract options are exercised, the total award of up to $24.7 million will support the preclinical, manufacturing and clinical development activities necessary to advance heat stable RiVax™ with the FDA.

“The exercise of this option validates Soligenix’s success on contractual work completed to date and reflects NIAID’s ongoing commitment to advance development of viable thermostabilization technologies that can be applied to important vaccine preparations,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “It also highlights the government’s commitment to identification and development of countermeasures to protect both the public and, more likely, first responders, in the event of ricin exposure.”

See also: NIAID Exercises Option on Soligenix Radiation Countermeasure

Tags: RicinThermostabilityVaccines

Related Posts

NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity
Biosecurity

U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity

April 13, 2022
New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs
Medical Countermeasures

New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs

April 10, 2022
Yersinia pestis
Funding News

NIH Awards $3M Grant to Albany Med for Plague Vaccine Development

April 8, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC